Complete Genomics Appoints Entrepreneur and Investor Lauren Selig to Board of Directors
Complete Genomics, a U.S.-based company specializing in end-to-end DNA sequencing platforms, reagents, and software, has announced the appointment of entrepreneur, investor, and film producer Lauren Selig to its board of directors. The appointment adds an experienced technology investor and business leader to the company’s leadership structure as Complete Genomics prepares for a new phase of growth and expansion.
Selig brings experience spanning entrepreneurship, investment, entertainment, emerging technologies, and scientific innovation. Her background includes leadership in companies and organizations working across artificial intelligence, biotechnology, space technology, media, and other frontier industries. Complete Genomics believes her broad experience will provide valuable strategic perspective as the company works to advance its sequencing technologies and strengthen its position in the global genomics and precision medicine markets.
The appointment is expected to take effect following the completion of the pending acquisition of Complete Genomics by Swiss Rockets AG. The proposed transaction has already received approval from MGI Tech shareholders, Chinese regulatory authorities, and the board of directors and shareholders of Swiss Rockets AG. The transaction remains subject to clearance from the Committee on Foreign Investment in the United States (CFIUS).
Once the transaction closes, Selig will join a board being assembled to support Complete Genomics as an independent, U.S.-anchored genomics company. The company is continuing to expand its board with leaders who bring experience in U.S. business, technology, innovation, and global commercialization.
Expanding Leadership as Complete Genomics Enters a New Phase
Complete Genomics has developed an end-to-end approach to DNA sequencing that encompasses sequencing instruments, reagents, and software. Its technologies are designed to support high-throughput genomic analysis while helping researchers and healthcare organizations obtain sequencing data efficiently and cost-effectively.
As genomics becomes increasingly important to biomedical research, drug discovery, disease diagnosis, and precision medicine, sequencing companies are facing growing demand for technologies that can deliver accurate results at scale.
Complete Genomics is positioning itself to participate in this expanding market by continuing to develop next-generation sequencing technologies and increasing access to genomic analysis.
The addition of Selig to the board comes at an important point in the company’s corporate development. The pending transaction with Swiss Rockets AG is expected to establish a new organizational structure and provide a platform for future expansion.
With experience investing in and supporting companies operating at the intersection of science and technology, Selig is expected to contribute to strategic discussions involving innovation, commercialization, partnerships, and long-term growth.
Lauren Selig Brings Diverse Technology and Investment Experience
Selig is the founder of Shake and Bake Productions and leads an investment fund focused on emerging companies and technologies.
Her investment interests span artificial intelligence, biotechnology, space, media, and other areas of frontier technology. Through her investment activities, she has supported companies seeking to commercialize technologies that could have significant long-term impact.
Her portfolio includes investments in companies such as LILA, Starcloud, Impulse Space, and Colossal.
These companies operate across different sectors, but share a common focus on developing technologies at the boundaries of established industries. Selig’s experience working with such companies gives her exposure to the challenges associated with taking emerging technologies from early-stage development into commercially viable businesses.
This experience is particularly relevant to Complete Genomics as the company seeks to advance its sequencing technologies and expand their use across research and healthcare applications.
In addition to her investment activities, Selig serves on the boards of organizations including XPRIZE, Pendrell, and Renatus Tactical Acquisition Corp. I.
Her involvement with innovation-focused organizations has provided her with experience in strategic planning, governance, technology development, and commercialization.
Experience Connecting Science With Commercialization
A major theme throughout Selig’s professional career has been the intersection of scientific innovation and commercial development.
Her investment portfolio includes companies working in areas such as synthetic biology and space infrastructure, where significant scientific and engineering advances must ultimately be converted into scalable commercial platforms.
That perspective could be valuable to Complete Genomics as the company works to translate sequencing innovations into products that can be adopted by researchers, pharmaceutical companies, healthcare providers, and other customers.
Genomics is a rapidly evolving field, and advances in sequencing technology can influence many areas of healthcare and life sciences.
High-throughput sequencing is increasingly being used in applications including genomic research, molecular diagnostics, drug development, population health, cancer research, and precision medicine.
However, the scientific potential of sequencing technologies must be matched by reliable manufacturing, scalable platforms, accessible pricing, user-friendly software, and effective commercial strategies.
Complete Genomics believes Selig’s experience across multiple technology sectors will help the company navigate these opportunities.
Swiss Rockets AG Transaction Creates New Corporate Direction
Selig’s appointment is directly connected to Complete Genomics’ pending acquisition by Swiss Rockets AG.
The transaction is expected to play an important role in shaping the company’s future structure and strategy. The acquisition has received several required approvals, although clearance from CFIUS remains outstanding.
Following the completion of the transaction, Dr. Vladimir Cmiljanovic, founder and chief executive officer of Swiss Rockets AG, is expected to become chairman and chief executive officer of Complete Genomics.
The planned leadership structure reflects an effort to combine expertise in biotechnology, technology development, business strategy, and global innovation.
According to Cmiljanovic, Selig’s background in entrepreneurship, frontier technologies, and global innovation makes her a strong addition to the company’s board.
He noted that Complete Genomics is building a board with the strategic capabilities needed to support the company as it develops into an independent U.S.-anchored organization.
Cmiljanovic also emphasized Selig’s experience in building companies, investing in transformative technologies, and working with major innovation organizations.
Supporting the Future of Genomics and Precision Medicine
The appointment comes as genomics continues to play a larger role in modern medicine.
DNA sequencing has evolved significantly over the past several decades, moving from a specialized research technique into an increasingly important tool for clinical research and healthcare.
Sequencing can provide detailed information about genetic variation, helping scientists understand the biological mechanisms underlying disease.
In oncology, genomic information can help researchers identify mutations associated with tumor development and investigate potential treatment targets. In rare diseases, sequencing can assist researchers and clinicians in identifying genetic changes that may contribute to unexplained conditions.
The technology also supports pharmaceutical research by helping scientists understand disease biology, identify potential drug targets, and study patient populations.
As these applications continue to expand, demand is increasing for sequencing platforms that can process large numbers of samples while maintaining accuracy, reliability, and cost efficiency.
Complete Genomics is seeking to address these needs through its integrated sequencing platforms, reagents, and software.
Board-Level Expertise for Global Expansion
The company’s decision to add Selig to its board reflects the importance of strategic leadership as Complete Genomics enters its next phase.
Board members with experience across technology, finance, investment, business development, and commercialization can help companies navigate complex growth environments.
For Complete Genomics, the combination of genomics expertise and broader technology-sector experience could be particularly important as it seeks to expand its international presence.
Although genomics is a global industry, companies operating in the sector must navigate different regulatory environments, healthcare systems, commercial markets, and research ecosystems.
A board with international networks and experience across multiple industries may help identify strategic opportunities and partnerships.
Selig’s investment background could also provide perspective on emerging technologies that may converge with genomics, including artificial intelligence, computational biology, synthetic biology, and other data-driven technologies.
AI and Genomics Could Create New Opportunities
Artificial intelligence is increasingly becoming an important component of genomic research.
Modern sequencing technologies can generate enormous amounts of biological data, creating opportunities for AI and machine learning systems to identify patterns and relationships that may be difficult to detect through conventional analysis.
AI can potentially support applications such as variant interpretation, biomarker discovery, disease prediction, drug discovery, and genomic data analysis.
Selig’s experience investing in artificial intelligence and other emerging technologies could therefore complement Complete Genomics’ scientific and technical capabilities.
The convergence of sequencing and AI may become increasingly important as genomic datasets continue to grow and researchers seek more sophisticated tools to interpret biological information.
Leadership Perspectives on the Appointment
Dr. Vladimir Cmiljanovic said Selig’s experience is particularly relevant to the company’s next stage of development. He highlighted her combination of entrepreneurial experience, investment expertise, and exposure to frontier technologies.
According to Cmiljanovic, her perspective and global network are expected to provide value to Complete Genomics as it establishes itself as an independent U.S.-anchored company.
Selig also expressed enthusiasm about joining the board.
She said Complete Genomics is developing technologies with the potential to contribute to healthcare globally and indicated that she looks forward to working with the company’s directors and leadership team to expand its impact and accelerate innovation in genomics and precision medicine.
Radoje Drmanac, founder and chief scientific officer of Complete Genomics, also welcomed the appointment.
Drmanac emphasized Selig’s ability to understand how scientific breakthroughs can be transformed into products and companies capable of reaching customers at scale.
That capability, he said, will be important as Complete Genomics works to commercialize its next generation of sequencing technologies and expand access to high-throughput and cost-effective genomic analysis.
The appointment of Lauren Selig marks another step in Complete Genomics’ efforts to strengthen its leadership as it prepares for the potential completion of the Swiss Rockets AG acquisition.
If the transaction closes following the required regulatory clearance, the company will enter a new phase as an independent, U.S.-anchored organization with ambitions to expand its role in the global genomics market.
Selig’s experience across entrepreneurship, investment, artificial intelligence, biotechnology, space technology, and media provides a diverse perspective that could support the company as it evaluates new commercial and technological opportunities.
At the same time, Complete Genomics will continue focusing on its core mission of advancing DNA sequencing through integrated platforms, reagents, and software.
As sequencing becomes increasingly central to precision medicine and biomedical research, the ability to deliver high-throughput, reliable, and cost-effective genomic technologies will remain an important competitive factor.
With a strengthened board and a new corporate structure on the horizon, Complete Genomics is positioning itself to pursue further growth while continuing to advance sequencing technologies that could support researchers, healthcare organizations, and patients around the world.
About Complete Genomics
Complete Genomics is a U.S.-based life sciences company providing end-to-end DNA sequencing platforms, reagents and software solutions.* Since its founding in 2005, the company has contributed to more than 10,900 scientific publications and continues to advance high-throughput, cost-effective genomics. For more information, visit www.completegenomics.com.
About Swiss Rockets AG
Swiss Rockets AG is an incubator and accelerator supporting the growth of biotech and precision healthcare companies with a focus on oncology. For more information, visit www.swissrockets.com.